Milrinone infusion is one of the few “non-device” therapies for patients with New York Heart Association class IV, stage D heart failure, but it has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation. Is it beneficial overall? In this video, AJM Editor-in-Chief Joseph S. Alpert, MD, discusses new research on the safety and efficacy of milrinone infusion in treating end-stage heart patients with a history of ventricular tachyarrhythmia.
You can read “Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tacharrhythmias” in the July 2020 issue of the American Journal of Medicine at amjmed.com.
https://www.youtube.com/watch?v=yhhYdwJ-quA
